{
  "docId": "019de074-3cc2-7451-b551-f16094d96b35",
  "docSlug": "3309edf11a92b656dd98b92129b54a19",
  "documentTitle": "Recursion Pharmaceuticals | Investor Day Presentation Deck | 143 slides",
  "authorId": "recursion-pharmaceuticals",
  "authorName": "Recursion Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 115,
  "pageCount": 120,
  "prevPage": 114,
  "nextPage": 116,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 27,
  "notes": "The slide uses a table to quantify the addressable market and a callout box to link preclinical data to the study design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-3cc2-7451-b551-f16094d96b35/115",
  "deckHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35",
  "deckJsonHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35.json",
  "deckAnchorHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35#slide-115",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.53,
        "y": 0.73
      },
      "kind": "callout",
      "text": "Preclinical data with REC-4881 at clinically relevant exposures in HCC and Ovarian PDX mouse models gives confidence to pursue other mutant cancer types",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12fad532-87a2-436a-81c3-11a3035b0418",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.5,
        "y": 0.3
      },
      "kind": "list",
      "text": "AXIN1 and APC genes covered by commercially available NGS panels and liquid biopsy detection assays; FDA guidance supports utility of ctDNA as patient selection; Multiple tumor types will inform study design and patient selection",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5349b3c0-3f40-4a50-a293-2783fc226212",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.12,
        "x": 0.32,
        "y": 0.82
      },
      "kind": "metric",
      "text": "~32,000",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66ca0ccd-0169-4976-adc8-25dbd43c2a26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Represents higher of either AXIN1 or APC alteration frequency; obtained from cbioportal.org. Represents 2L prevalance estimates; obtained from DRG. HCC treatable population includes potential 1L treatment regimen. https://www.fda.gov/media/158072/download",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb78e2b1-8eca-4304-a560-fde334743fce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "table",
      "text": "Tumor Type, Alteration Frequency, Treatable Population (US+EU5); LUAD 11% 10,000; HCC 12% 7,600; Prostate 11% 5,600; Bladder 8% 3,700; Esophageal 7% 2,000; Endometrial 12% 1,500; PDAC 2% 1,000; Ovarian 1% 350; TNBC 2% 200",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8822051f-e5b2-4e45-8db3-08e21f420743",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Disease Overview : AXIN1/APC mutant cancers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c597d676-3c04-45ff-875e-93d4dbf94a86",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 15,
      "beatId": "136386a5-6141-40a4-88e2-1f9e9bd0026c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Recursion's solution, including its technology, approach, and progress in drug discovery.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 120,
      "from": 15,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "781e998b-dc37-46ea-ab12-3271a3953fda",
      "evidence": "The document presents Recursion's solution, including its technology, approach, and progress in drug discovery.",
      "position": 1,
      "objective": "How can Recursion's technology and approach improve drug discovery outcomes?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}